Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
Sources News Release
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 10/08/2010
Year Published: 2010
Resource Type: Article
Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
Abstract: CALIFON, NJ, BASEL, Switzerland and DRESDEN, Germany # August 10, 2010 - Anavex Life Sciences Corp. (#ANAVEX#) (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (#Genesis#) and ABX-CRO Advanced Pharmaceutical Services (#ABX-CRO#) to begin clinical studies and regulatory filings for ANAVEX 2-73, its lead compound for the treatment of Alzheimer#s Disease.
#Selecting Genesis and ABX-CRO to advance ANAVEX 2-73 to the clinical r...
To read the full release go to http://www.sources.com/Releases/NR943.htm
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.